Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diodone Acid SCHEMBL468504 | 0.81 | AKR1B1 (0.39) | ALDH1A1MAPTSMN1; SMN2CA12CA9 | |
| SCHEMBL16160299 | 0.70 | KMT2A (0.42) | NPC1MITFS1PR4ALDH1A1MAPT | |
| SCHEMBL2876964 | 0.64 | — | — | |
| SCHEMBL15495572 | 0.60 | SRC (0.36) | NPC1MITFS1PR4ALDH1A1MAPT | |
| SCHEMBL12017379 | 0.60 | SMN1; SMN2 (0.38) | NPC1MITFS1PR4ALDH1A1MAPT | |
| SCHEMBL11955666 | 0.59 | GSK3A (0.55) | ALDH1A1MAPTRAB9ASMN1; SMN2CA12 | |
| SCHEMBL21233122 | 0.57 | ALDH1A1 (0.36) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL22445331 | 0.57 | KDM4C (0.36) | NPC1MITFS1PR4ALDH1A1MAPT | |
| SCHEMBL5091798 | 0.55 | TSHR (0.44) | ALDH1A1RAB9ASMN1; SMN2POLB | |
| SCHEMBL12133543 | 0.55 | POLB (0.37) | NPC1MITFS1PR4ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501242-B2 | Methods and compositions for treating neoplasia | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120156212-A1 | METHODS AND COMPOSITIONS FOR TREATING NEOPLASIA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156212-A1 | METHODS AND COMPOSITIONS FOR TREATING NEOPLASIA | TYMS, UNG, TYMP | NPC1 939/4885MITF 2667/4885S1PR4 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.